{"schema_version":"1.0","type":"article","title":"More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%?","url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.md","lang":"en","date":"2026-08-05","publish_at":"2026-08-05T08:00:00+08:00","updated_at":"2026-08-05","category":"商業分析系列","topic":"商業分析系列","tags":["Alnylam","Amvuttra","RNA interference","ATTR amyloidosis","small nucleic acid drugs","biotech valuation","Taiwan biotech","clinical data","biotech business analysis"],"summary":"Amvuttra surpassed $1 billion in quarterly sales, yet Alnylam cut its TTR guidance and lost 28% in one day. The reset was not about RNAi technology failing; it was about pent-up demand normalizing, revenue concentration and the timing gap before a second commercial pillar arrives.","key_points":[],"facts":[],"sections":["01 | Strong Results, but the Bad News Was in the Outlook","02 | $200 Million Is Not Much; 86% Concentration Is","03 | Wainua's Phase 3 Miss Should Not Be Rewritten as an RNAi Failure","04 | Nucresiran Is Next, but the Market Must Wait for Clinical Evidence, Not a Slogan","05 | Taiwan Has a Clinical Foothold, but No Evidence of a Direct Beneficiary Stock","06 | What to Watch Next: Do Not Focus Only on Next Quarter's Revenue","Conclusion | The Technology Did Not Break; the Valuation Shifted Gears First","References","Disclaimer"],"references":[{"title":"[Alnylam, 2026 Q2 financial results and full-year guidance update]","source":"","date":"","url":"https://investors.alnylam.com/press-release?id=29986"},{"title":"[Alnylam, 2026 Q2 Form 10-Q]","source":"","date":"","url":"https://alnylampharmaceuticalsinc.gcs-web.com/static-files/df2ac46c-f252-4864-97e7-02db276e70db"},{"title":"[U.S. Food and Drug Administration, Amvuttra (vutrisiran) prescribing information]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215515s006lbl.pdf"},{"title":"[Ionis, CARDIO-TTRansform topline results]","source":"","date":"","url":"https://ir.ionis.com/node/34896"},{"title":"[U.S. Food and Drug Administration, Attruby approval announcement]","source":"","date":"","url":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis"},{"title":"[ClinicalTrials.gov, TRITON-CM (NCT07052903)]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07052903"},{"title":"[Nasdaq, ALNY historical trading data]","source":"","date":"","url":"https://www.nasdaq.com/market-activity/stocks/alny/historical"},{"title":"[Oneness Biotech, SNS851 Phase 1 and co-development announcement]","source":"","date":"","url":"https://onenessbio.com/en/a-phase-1-clinical-trial-of-sns851-has-been-approved-by-australia-hrec-and-acknowledged-by-australia-tga/"},{"title":"[Microbio, SNS851 co-development announcement]","source":"","date":"","url":"https://www.twmicrobio.com/tw/%E9%87%8D%E5%A4%A7%E8%A8%8A%E6%81%AF-17/"},{"title":"[Genomics, short-chain nucleic acid and siRNA API capabilities (2024 annual report)]","source":"","date":"","url":"https://www.genomics.com.tw/upload/2025_09_11/2_202509111525141hcglwe9Y0.pdf"},{"title":"[Taipei Exchange, IntelliGene (7832) company overview and RNAi/delivery research and development]","source":"","date":"","url":"https://www.tpex.org.tw/storage/emerging_register/2025/04/1745477059_14400_CH_7832.pdf"},{"title":"[IntelliGene, core technologies and IG-001/IG-002]","source":"","date":"","url":"https://www.intelli-gene.com/tech"},{"title":"Information verified through July 31, 2026 (UTC+8).","source":"","date":"","url":""}],"images":[{"alt":"Figure 1","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-01.png"},{"alt":"Figure 2","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-02.png"},{"alt":"Figure 3","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-03.png"},{"alt":"Figure 4","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-05）。More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%?。https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-05-alnylam-amvuttra-ttr-growth-reset.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}